A potential novel treatment for cirrhosis‐related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease

Abstract

AbstractAimsAdvanced chronic liver disease and advanced chronic liver disease‐related ascites have a high mortality. The pharmacological treatment of ascites and fluid overload has changed little over time. Empagliflozin, a sodium‐glucose cotransporter type 2 inhibitor is an untested potential novel treatment in cirrhosis, as it has survival benefits in heart failure, which has similar pathophysiological fluid overload mechanisms. Before investigating empagliflozin's potential benefit in cirrhosis, its safety must be addressed.MethodsTen participants (five each with compensated or decompensated advanced chronic liver disease, based on Child–Pugh class) received empagliflozin 10 mg orally daily for 4 weeks with 2 weeks follow‐up. Empagliflozin safety, pharmacokinetics and pharmacodynamics were investigated.ResultsIn total, eight patients (80%) reported an adverse event, and three patients (30%) experienced a serious adverse event, one of which was attributed to empagliflozin. Overall, the frequency of adverse events was similar to previous phase 3 trials of gliflozins. Higher plasma empagliflozin concentrations did not significantly increase the risk of adverse events.ConclusionsFour‐week treatment with empagliflozin was safe and well tolerated in patients with advanced chronic liver disease. These preliminary data support assessment of long‐term treatment on disease‐related and mortality outcomes in patients with cirrhosis through randomized control trials.